Literature DB >> 26960437

[Endoscopic therapy for gastroduodenal neuroendocrine neoplasms].

S Maasberg1, C Jürgensen1, F Scheerer2, R Pschowski1, S Felder1, N Begum3, B Wiedenmann1, A Pascher4, U-F Pape5.   

Abstract

Neuroendocrine neoplasms (NEN) represent a group of potentially malignant tumors, which can be located in every section of the gastrointestinal tract, the pancreas and the bronchopulmonary system. Gastroduodenal NENs have a relatively good prognosis in comparison to other subentities, e.g. pancreatic or ileojejunal NENs. In the stomach there are four different types of NENs, while in the duodenum there are five types and all vary in the malignant potential and the therapeutic approach. Due to the simple access endoscopic methods not only have diagnostic but also important therapeutic relevance in this subgroup. Lesions smaller than 1 cm can easily be resected with forceps or snare resection and for larger lesions up to 2 cm more invasive strategies, such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) are available. Important criteria in gastric NEN for the risk evaluation of endoscopic treatment alone are the size of the lesion, depth of invasion and the tumor biology, e.g. neuroendocrine tumor (NET) G1/G2 versus neuroendocrine carcinoma (NEC) G3. In duodenal NEN the aforementioned risk factors also apply and in addition only lesions outside the ampulla of Vater should be endoscopically resected whereas periampullary lesions need to be addressed surgically. As an individualized therapeutic approach the possibility of a combined endoscopic and laparoscopic resection technique exists. Follow-up endoscopic investigations are necessary, especially in gastric type 1 NENs, which have a tendency to relapse.

Entities:  

Keywords:  Endoscopic therapy; Gastroduodenal; Neuroendocrine carcinoma; Neuroendocrine tumor; Zollinger-Ellison syndrome

Mesh:

Year:  2016        PMID: 26960437     DOI: 10.1007/s00104-016-0157-6

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  28 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas).

Authors:  Robert T Jensen; Guido Rindi; Rudolf Arnold; José M Lopes; Maria Luisa Brandi; Wolf O Bechstein; Emanuel Christ; Babs G Taal; Ulrich Knigge; Hakan Ahlman; Dik J Kwekkeboom; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2007-02-20       Impact factor: 4.914

3.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.

Authors:  Günter Klöppel; Anne Couvelard; Aurel Perren; Paul Komminoth; Anne-Marie McNicol; Ola Nilsson; Aldo Scarpa; Jean-Yves Scoazec; Bertram Wiedenmann; Mauro Papotti; Guido Rindi; Ursula Plöckinger
Journal:  Neuroendocrinology       Date:  2009-08-28       Impact factor: 4.914

4.  Republished: gastric neuroendocrine neoplasms and related precursor lesions.

Authors:  Stefano La Rosa; Alessandro Vanoli
Journal:  Postgrad Med J       Date:  2015-03       Impact factor: 2.401

5.  A clinical perspective on gastric neuroendocrine neoplasia.

Authors:  Ben Lawrence; Mark Kidd; Bernhard Svejda; Irvin Modlin
Journal:  Curr Gastroenterol Rep       Date:  2011-02

6.  Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.

Authors:  G Rindi; C Bordi; S Rappel; S La Rosa; M Stolte; E Solcia
Journal:  World J Surg       Date:  1996-02       Impact factor: 3.352

7.  The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.

Authors:  Ursula Ploeckinger; Guenter Kloeppel; Bertram Wiedenmann; Ruediger Lohmann
Journal:  Neuroendocrinology       Date:  2009-09-23       Impact factor: 4.914

Review 8.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

Review 10.  Advances, problems, and complications of polypectomy.

Authors:  Andrea Anderloni; Manol Jovani; Cesare Hassan; Alessandro Repici
Journal:  Clin Exp Gastroenterol       Date:  2014-08-30
View more
  1 in total

1.  Relevant risk factors and the prognostic impact of positive resection margins after endoscopic resection of gastrointestinal neuroendocrine tumors.

Authors:  Jing Wen; Bin Yan; Jing Yang; Zhongsheng Lu; Xuqiang Bian; Jin Huang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-11-04       Impact factor: 1.195

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.